Allogeneic BMT is currently used for the treatment of a variety of neoplastic diseases. GVHD and relapse of the tumor remain significant obstacles limiting the clinical efficacy of BMT. We examined whether the adoptive transfer of NK cells could augment the antitumor effects of allogeneic BMT in advanced tumor-bearing mice. Mice received the MCA38 colon adenocarcinoma and after 10 days and were treated with allogeneic BMT and activated NK cells of donor type. The results demonstrated that the transfer of activated NK cells resulted in significant increases in survival. There was no evidence of GVHD in the mice receiving NK cells even though tumor-bearing mice receiving allogeneic BMT alone demonstrated severe GVHD pathology and morbidity related to the transfer of T cells with the marrow. To determine the mechanism by which the NK cells were inhibiting GVHD, neutralizing antibodies to the immunosuppressive cytokine, TGF-0, were administered in vivo. Mice receiving these antibodies and the NK cells now exhibited severe GVHD demonstrating that NK cells prevent GVHD at least in part through the production of TGF-/3. These results suggest that GVT and GVHD are dissociable phenomena.
|Original language||English (US)|
|State||Published - 1996|
ASJC Scopus subject areas
- Agricultural and Biological Sciences (miscellaneous)
- Biochemistry, Genetics and Molecular Biology(all)
- Cell Biology